Alveolar macrophages (AMs) are multitasking cells that maintain lung homeostasis by clearing apoptotic cells (efferocytosis) and performing antimicrobial effector functions. Different PRRs have been described to be involved in the binding and capture of non-opsonized Streptococcus pneumoniae, such as TLR-2, mannose receptor (MR) and scavenger receptors (SRs). However, the mechanism by which the ingestion of apoptotic cells negatively influences the clearance of nonopsonized S. pneumoniae remains to be determined. In this study, we evaluated whether the prostaglandin E2 (PGE 2 ) produced during efferocytosis by AMs inhibits the ingestion and killing of non-opsonized S. pneumoniae. Resident AMs were pre-treated with an E prostanoid (EP) receptor antagonist, inhibitors of cyclooxygenase and protein kinase A (PKA), incubated with apoptotic Jurkat T cells, and then challenged with S. pneumoniae. Efferocytosis slightly decreased the phagocytosis of S. pneumoniae but greatly inhibited bacterial killing by AMs in a manner dependent on PGE 2 production, activation of the EP2-EP4/cAMP/PKA pathway and inhibition of H 2 O 2 production. Our data suggest that the PGE 2 produced by AMs during efferocytosis inhibits H 2 O 2 production and impairs the efficient clearance non-opsonized S. pneumoniae by EP2-EP4/cAMP/PKA pathway.
Introduction
Alveolar macrophages (AMs) maintain airway homeostasis, serve as the first line of defense against microorganisms and function in the clearance of apoptotic cells (i.e. efferocytosis) during tissue injury. Previous research from our laboratory and others has shown that phagocytosis of apoptotic cells triggers the release of prostaglandin E2 (PGE 2 ) and other antiinflammatory mediators, such as IL-10 and TGF-b. 1-3 PGE 2 , the major lipid mediator synthesized by macrophages during the inflammatory response, 4 is derived from cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) activities on released arachidonic acid. PGE 2 functions through four different G protein-coupled E prostanoid (EP) receptors. EP1 is coupled to Gq, resulting in increased intracellular Ca 2+ . EP3 is coupled to Gi and leads to a reduction in cAMP, whereas EP2 and EP4 are coupled to Gs, resulting in increased intracellular cAMP. Several studies have shown that increases in cAMP account for the inhibitory effect of PGE 2 . [5] [6] [7] [8] An increased cAMP concentration in AMs stimulates protein kinase A/exchange protein directly activated by cAMP (PKA/EPAC), thereby inhibiting reactive oxygen species (ROS) generation and bacterial killing. 8 Moreover, inhibition of the membrane translocation of p40phox and ROS production caused by PGE 2 are reversed when AMs challenged with anti-Klebsiella pneumoniae IgG are treated with an inhibitor of PKA-RII.
Phagocytosis of apoptotic cells by macrophages promotes the uncontrolled proliferation of Trypanosoma cruzi via a mechanism that is dependent on PGE 2 , TGF-b and polyamine production. Indeed, a previous study showed that treatment of infected animals with COX inhibitors abolishes parasitemia. 9 A different study showed that instillation of apoptotic cells in a model of endotoxin-induced pulmonary inflammation inhibited inflammatory cell recruitment in bronchoalveolar lavage fluid and the lung and decreased proinflammatory mediator production. 10 Additionally, we previously demonstrated that inhibition of FcRmediated phagocytosis due to AM efferocytosis is mediated by the PGE 2 /EP2 receptor/cAMP axis. 3 Patients with asthma, chronic obstructive pulmonary disease (COPD) or who have inhaled toxic agents accumulate a large number of apoptotic cells due to a deficiency in the phagocytosis of these cells mediated primarily by AMs. Statins and corticosteroids have been used as adjuvant therapies in patients with COPD, to enhance efferocytosis. 11, 12 However, improvement in efferocytosis by these drugs also increases the susceptibility of mice to S. pneumoniae infection. 13 We previously demonstrated that instillation of apoptotic cells in vivo induced an increase in PGE 2 , bacterial load in the lung and spread of the infection to the bloodstream. 3 However, further definition of the role of non-opsonic receptors during the infection of AMs via apoptotic cells ingestion is necessary. In this study, we hypothesized that PGE 2 produced during efferocytosis mediates a reduction in the effector functions of AMs infected with non-opsonized S. pneumoniae.
Materials and methods

Materials
Tryptic soy broth (TSB) and blood agar base n 2 were purchased from Acumedia (Baltimore, MD, USA). RPMI 1640 medium, FBS, indometacin, FITC, trypan blue, PBS and campothecin were obtained from Sigma-Aldrich (St. Louis, MO, USA). An EP2 agonist (Butaprost), an EP4 agonist (CAY10598) and PGE 2 were obtained from Cayman Chemical (Ann Arbor, MI, USA). EP2 (AH 6809) and EP4 (AH23848) antagonists, activator of adenylyl cyclase (forskolin), inhibitor of adenylyl cyclase (SQ 22536), PKA inhibitors (KT5720, H89 dihydrochloride and PKI 6-22 amide) and a PKA activator (8-Bromo-cAMP) were purchased from Tocris Bioscience (Bristol, UKP). Saponin was purchased from Acros Organic (Bridgewater, NJ, USA). Gentamycin was obtained from Life Technologies (Carlsbad, CA, USA). Annexin V and propidium iodide (PI) were purchased from BD Biosciences (San Jose, CA, USA). Cell Tracer Far Red TM was purchased from Thermo Fisher Scientific (Waltham, MA, USA).
Animals
Female Wistar rats ($150 g) were obtained from the Centro Multidisciplinar para Investigac¸a˜o Biolo´gica -CEMIB/UNICAMP, Sa˜o Paulo, Brazil. The animals were treated according to the Brazilian College of Animal Experimentation guidelines for the use of experimental animals. The institution's animal ethics committee approved the housing conditions and experimental procedures (protocol numbers 28/2011 and 36/2016).
AMs
Resident AMs were obtained as previously described by Peters-Golden et al. 14 Briefly, AMs were obtained via bronchoalveolar lavage (BAL) and maintained in RPMI 1640 medium without FBS for 1 h. The medium was then replaced with complete RPMI 1640 with 10% FBS and 50 mg/ml gentamicin, and the cells were cultured overnight (18 h).
Generation of apoptotic cells
Jurkat cells were used as a source of apoptotic cells. These cells were incubated with camptothecin (2 mg/ ml) for 5 h as previously described. 3 The percentage of early (Annexin + /PI -) and late (Annexin + /PI + ) apoptotic cells was determined by flow cytometry (FACSCanto TM ; BD Biosciences) after labeling with Annexin V/PI, as previously described. 15 Streptococcus pneumoniae and FITC-labeled bacteria S. pneumoniae cells (ATCC 49619) were grown in TSB at 37 C at 200 rpm for 5 h. The estimated number of bacteria was determined using a standard curve [OD ( ¼ 600 nm) vs. CFU] previously established in our laboratory. The bacterial inoculum was confirmed by CFU recovery on blood agar plates. S. pneumoniae cells were conjugated with FITC as previously described. 16 
Phagocytosis assay
Phagocytosis of FITC-labeled S. pneumoniae (S. pneumoniae-FITC) was assessed as previously described. 7, 17 Briefly, 2.5 Â 10 5 AMs were incubated in black-wall/ clear-bottom sterile 96-well microplates for 16 h in RPMI 1640 medium. The culture medium was then removed and replaced with warm, serum-free RPMI 1640 medium. Inhibitors and antagonists were added 30 min prior to the addition of apoptotic cells and/or cells incubated with the bacteria. Apoptotic cells were added to the culture in a 3:1 AC:AM ratio for 1 h as previously described, 3 followed by incubation with 100 S. pneumoniae-FITC cells:1 AM (MOI of 100) for 3 h. Trypan blue (250 mg/ml, pH 4.4) was added to the culture for 10 min to quench the fluorescence of extracellular bacteria. The fluorescence intensity was measured using a microplate fluorometer (485ex/ 535em, BioTek, Synergy H1). The results are expressed as the percent phagocytosis compared with a control containing S. pneumoniae + AMs (% of control).
Apoptotic Jurkat cells were stained with 5 mM Cell Tracer Far Red TM and incubated with AMs for 4 h. To evaluate efferocytosis by AMs, the percentage of intracellular stained positive cells was evaluated by flow cytometry (BD FACSCanto TM ).
Survival of S. pneumoniae in AMs
AMs (2 Â 10 5 cells) were incubated overnight in 96-well microplates. The medium was then removed and replaced with warm serum-free RPMI 1640 medium. Inhibitors, agonists and antagonists were added 30 min prior to the addition of apoptotic cells and/or cells infected with S. pneumoniae. Apoptotic cells were added to the culture in a 3:1 AC:AM ratio for 1 h or 18 h as previously described, 3 followed by incubation with 50 viable S. pneumoniae cells:1 AM (MOI of 50) for 3 h for phagocytosis. The AMs were washed three times and incubated for 4 h to evaluate the survival of S. pneumoniae within the AMs. The cells were lysed with 200 ml TSB + 0.5% saponin, and serial dilutions of the cell lysate were plated onto blood agar plates. CFU recovery was evaluated after 24 h.
Quantification of NO
NO was measured indirectly by quantifying nitrite metabolites, as previously described by Griess 18 AMs were incubated with or without apoptotic cells, followed by incubation with S. pneumoniae. The culture supernatant was collected at different time points and quantified colorimetrically.
Quantification of H 2 O 2
Intracellular levels of H 2 O 2 were determined as previously described by Houde et al. 19 Briefly, 2.5 Â 10 5 AMs were incubated for 30 min in 96-well microplates in the presence or absence of a PKA inhibitor (KT5720: 1 mM; H89: 10 mM; PKI 6-22 : 5 mM), and apoptotic cells (3:1 AC:AM ratio) were added to the culture for 1 h followed by challenge with S. pneumoniae for 30 and 90 min in the presence of 25 mM 123-DHR. The fluorescence intensity was measured using a microplate fluorometer (485ex/535em, BioTek, Synergy H1). The data are expressed as the percentage of relative changes in H 2 O 2 production (% of AMs + Sp).
Statistical analysis
The results were analyzed using the statistical program Prism 5.0 (GraphPad Software, La Jolla, CA, USA); the data are reported as mean AE SEM. Comparisons among three or more groups were assessed with ANOVA, followed by Dunnett's post-hoc test or twoway ANOVA followed by Bonferroni's post-test. Comparisons between two groups were assessed using t-test analyses. Differences were considered significant if the P-values were < 0.05.
Results
PGE 2 /EP2/adenylyl cyclase/cAMP inhibits the phagocytosis of S. pneumoniae by AMs within the context of efferocytosis
Our group previously demonstrated that phagocytosis of apoptotic Jurkat cells by AMs induces PGE 2 production and promotes the inhibition of FcR-mediated phagocytosis. 3 Here, we investigate whether efferocytosis by AMs inhibits S. pneumoniae phagocytosis, as well as the role of PGE 2 in inhibiting the effector mechanisms of AMs. We evaluated AM efferocytosis using apoptotic Jurkat cells stained with Cell Tracer Far Red TM . After 4 h, $44% of AMs were able to phagocytose apoptotic cells ( Figure 1a ). AMs were also pretreated with EP2/EP4 antagonists, PKA inhibitors and cAMP inhibitor for 30 min and then co-cultured with Far Red-labeled Jurkat apoptotic cells, to evaluate the effect of these compounds in efferocytosis. The percentage of AMs positive for apoptotic cells-FAR Red + , as well as the MIF of these cells was evaluated. We found no significant differences of efferocytosis by AMs in the presence of different compounds. Percentage of AMs positive for apoptotic cells was as follows: AMs:
Furthermore, incubation of AMs with apoptotic cells inhibited the phagocytosis of S. pneumoniae ($30%) compared with the control (AMs + Sp). Inhibition of S. pneumoniae phagocytosis was partially reversed by pre-treatment with the non-selective COX enzyme inhibitor indomethacin. To demonstrate that PGE 2 could mimic the inhibition of S. pneumoniae phagocytosis observed during efferocytosis, AMs were pre-treated with exogenous PGE 2 and then challenged with S. pneumoniae. The addition of exogenous PGE 2 was more effective than apoptotic cells at inhibiting phagocytosis of the bacteria by AMs (Figure 1b) . PGE 2 inhibition of macrophage effector functions has been suggested to occur through EP2 and EP4 receptor-mediated cAMP activation. To evaluate the signaling pathways by which PGE 2 inhibits the effector functions of AMs containing apoptotic cells, AMs were pre-treated with the adenylyl cyclase inhibitor SQ 22536, incubated with apoptotic cells and challenged with S. pneumoniae. Adenylyl cyclase inhibition prevented the inhibitory effects of efferocytosis by AMs challenged with S. pneumoniae (Figure 1c) , which was correlated with decreased phagocytosis in cells treated with the adenylate cyclase activator (forskolin) (Figure 1d ). Because the phagocytosis of S. pneumoniae by AMs after efferocytosis was marginally inhibited compared with our previous observations of FcRmediated phagocytosis inhibition (! 50 of inhibition), 3 we investigated the effect of efferocytosis on the antibacterial activity of AMs. AMs + Sp). However, after 18 h of efferocytosis, the survival of the ingested S. pneumoniae within AMs was at least three times higher than in AMs incubated with apoptotic cells for 1 h (Figure 2a ). Moreover, when AMs were initially infected with S. pneumoniae and then incubated with apoptotic cells, we observed a higher number of S. pneumoniae compared with AMs + Sp or AMs + Sp + AC (data not shown). Exposure to apoptotic cells for 18 h promotes the production of inflammatory mediators by AMs and apoptotic cells. Because the main focus of this work was to evaluate how PGE 2 produced by efferocytosis could impair the effector functions of AMs against S. pneumoniae, we next evaluated the effect of apoptotic cells after 1 h of incubation with AMs. Pre-treatment with indomethacin prior to efferocytosis followed by challenge with S. pneumoniae abolished the efferocytosis-mediated inhibition of AM microbicidal activity (Figure 2b ). Previous research from our laboratory and others has shown that PGE 2 inhibits bacterial killing in macrophages via EP2 and EP4 receptors. 3, 7 To mimic the effect of PGE 2 during efferocytosis, AMs were pre-treated with PGE 2 , and EP2 (Butaprost) and EP4 (CAY10598) agonists, and bacterial killing was then evaluated. As expected, pretreatment with exogenous PGE 2 enhanced intracellular bacterial survival. Moreover, EP2 and EP4 agonists decreased bacterial killing compared with AM + Sp. However, a synergistic effect of microbicidal activity inhibition in AMs was observed in the presence of the EP2 + EP4 agonists (Figure 2b) .
Moreover, when AMs were incubated with EP2 (AH 6809) and EP4 (AH 23848) antagonists, S. pneumoniae survival was dramatically reduced compared with AMs exposed to apoptotic cells (Figure 2c ). However, we did not detect any synergistic or additive effect when combinations of both antagonists were used (Figure 2c ).
In addition, the effect of antagonists, agonists and inhibitors on phagocytosis and microbicidal activity was evaluated in a dose-dependent range from 10 mM to 0.1 mM (data not shown); as described in the figure legends, the lowest effective doses were used in the ensuing experiments. The concentration of antagonists, agonists and inhibitors was the same used in all microbicidal activity assays.
Efferocytosis impairs the microbicidal activity of AMs against S. pneumoniae through PGE 2 /cAMP/PKA
The relevant signaling cascades involved in the PGE 2mediated inhibition of bacterial killing during efferocytosis were then examined. AMs were pre-treated with SQ22536 in the presence of apoptotic cells and challenged with S. pneumoniae. Adenylyl cyclase inhibition greatly improved the microbicidal activity of AMs containing apoptotic cells (Figure 3a ). To determine whether increased cAMP dampened non-opsonic microbial clearance, AMs were incubated with forskolin and challenged with S. pneumoniae. Increased cAMP production favored bacterial survival within AMs at the levels observed during efferocytosis (Figure 3b ).
Next, we evaluated whether PKA activation via the increase in cAMP by PGE 2 /EP2-EP4 accounted for the decreased microbicidal activity detected during S. pneumoniae infection. In the presence of PKA inhibitors KT5720 and H89 dihydrochloride, AMs were able to reverse the inhibitory effects of PGE 2 produced during the phagocytosis of apoptotic cells (Figure 3c ). To confirm that PKA activation inhibited AM microbicidal activity, the cells were incubated with a PKA activator (8-bromo-cAMP) and challenged with S. pneumoniae, and we found that PKA activation increased bacterial survival within AMs when compared with AMs + Sp (Figure 3d ).
Efferocytosis decreases H 2 O 2 production by S. pneumoniae-infected AMs
Next we examined how efferocytosis impaired the killing of S. pneumoniae by assessing whether efferocytosis impairs microbicidal activity by decreasing the levels of NO and H 2 O 2 . AMs were co-cultured with or without apoptotic cells and challenged with S. pneumoniae for different periods of time; NO and H 2 O 2 were measured in the supernatant. Low NO levels were detected when AMs were infected with S. pneumoniae. Moreover, there was no difference in NO production by AMs incubated in the presence or absence of apoptotic cells after S. pneumoniae challenge (data not shown). Conversely, H 2 O 2 production was increased after 30 min and 90 min when AMs were infected with S. pneumoniae and the ingestion of apoptotic cells inhibited H 2 O 2 production after S. pneumoniae infection. Furthermore, pre-treatment with different PKA inhibitors was able to revert partially H 2 O 2 production after 30 min; however, this effect was more pronounced after 90 min of incubation of AMs co-cultured with apoptotic cells and challenge with S. pneumoniae (Figure 4 ). The concentration of PKA inhibitors in H 2 O 2 assay was the same used in microbicidal activity.
Discussion
In this study, we evaluated whether PGE 2 produced during efferocytosis impairs the effector functions of AMs against non-opsonized S. pneumoniae. We found that efferocytosis by AMs had modest inhibitory effects on phagocytosis of S. pneumoniae but greatly inhibited bacterial killing by AMs in a manner dependent on PGE 2 production. The deficiency of bacterial killing ability was mediated via the EP2-EP4/cAMP/PKA pathway and inhibition of H 2 O 2 production. Lower respiratory tract infections are among the major causes of death, 20 especially infections caused by Gram-positive bacteria such as S. pneumoniae. [21] [22] [23] AMs are the most important cells involved in the clearance of apoptotic cells and defense against different microorganisms in the lung. COPD is characterized by defective efferocytosis leading to an intense accumulation of apoptotic cells in the lung and bronchoalveolar space. Moreover, patients with COPD are more prone to developing pneumonia, and S. pneumoniae is the most frequent bacterial lung infection in these patients. 24 We previously demonstrated that efferocytosis by AMs promotes inhibition of FcR-mediated phagocytosis and killing. PGE 2 is the major soluble mediator responsible for the deleterious effects observed during efferocytosis. 3 Our results demonstrate that efferocytosis by AMs has a modest inhibitory effect on the phagocytosis of S. pneumoniae. Treatment with the COX inhibitor indomethacin and an adenylyl cyclase inhibitor was able to reverse the inhibition of S. pneumoniae phagocytosis caused by efferocytosis ( Figure 1 ). AMs incubated in the presence of the same ratio of apoptotic cells (3:1) were not able to inhibit the phagocytosis of non-opsonized S. pneumoniae ($32%), as was previously observed with the Fc receptor ($60%). Thus, these results suggest that the inhibitory effect of efferocytosis mediated by PGE 2 on AMs is less effective on non-opsonic phagocytosis compared with the Fc receptor. 3 IgG-FcR activation induces phosphorylation of ITAM-associated proteins, such as Syk/PI3K and Akt, 25 whereas other receptors such as SR-A lead to activation of the Src family and PI3 kinases AKT/MAPK and Rac. 26 Therefore, efferocytosis by AMs can promote inhibition of phagocytosis by the Fc receptor but has only a weak effect through non-opsonized S. pneumoniae.
Next, we evaluated whether efferocytosis by AMs could affect their microbicidal activity against S. pneumoniae. Ingestion of apoptotic cells impaired bacterial killing, and treatment of AMs with a COX inhibitor or EP2 and EP4 antagonists reversed the inhibitory effects mediated by efferocytosis. Exposure of AMs to PGE 2 or an EP2 or EP4 agonist impaired S. pneumoniae killing, with a synergistic effect when AMs were incubated with EP2 plus EP4 agonists. Previously published data support our findings: Aronoff et al. demostrated that EP2 deficiency increased the survival of mice and improved the clearance of S. pneumoniae. 27 We also reported a decrease in bacterial burden in the lung and bloodstream in EP2 -/mice infected with S. pneumoniae compared with WT mice. 3 In the present study, we demonstrate that EP4, in addition to EP2, is involved in the inhibitory effects of PGE 2 in AMs. Aronoff et al. 27 suggested that infection with S. pneumoniae induces PGE 2 production from cells other than 
